▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Peter Stephens

TMFstockpicker

Peter is a Healthcare Specialist at The Motley Fool.

Recent Articles by Peter Stephens

Jan 26, 2014 by Peter Stephens

Novartis: Running Fast to Stand Still?

Novartis' recent setback may not be all bad news for the company’s long-term prospects.

Jan 26, 2014 by Peter Stephens

3 Reasons to Focus on Diabetes

With demand for diabetes drugs set to increase rapidly, AstraZeneca, Bristol-Myers Squibb, and Pfizer appear to be well placed to benefit.

Jan 22, 2014 by Peter Stephens

Why Medtronic Is The Early Bird That Could Catch The Worm

Early FDA approval could make Medtronic a stock to watch.

Jan 21, 2014 by Peter Stephens

Who Cares About Guidance, Anyway? Investors in St. Jude, That's Who!

Improved sales in Q4 mean that St Jude Medical has raised its guidance for the quarter. The stock could be one to watch in 2014.

Jan 19, 2014 by Peter Stephens

Divestment Is the Name of the Game for Johnson & Johnson

Recent news flow highlights the encouraging progress made by Johnson & Johnson (JNJ) as it seeks top-line growth.

Jan 19, 2014 by Peter Stephens

Is the Uncertainty at Novartis a Game-Changer for Investors?

Recent management changes at Novartis AG (NVS) is something for shareholders to note.

Jan 19, 2014 by Peter Stephens

3 Ways to Get Wealthier (and Healthier)

A recent study shows Americans are getting healthier. How could they get wealthier, too?

Jan 19, 2014 by Peter Stephens

A Roller-Coaster Ride With Intercept Pharmaceuticals

2014 has been full of (mainly) ups and (some) downs for Intercept Pharmaceuticals (ICPT).

Jan 9, 2014 by Peter Stephens

Boston Scientific Corporation: Your Next Turnaround Story?

Boston Scientific Corporation seems to have the potential to be a major turnaround play.

Jan 8, 2014 by Peter Stephens

Why the Risk/Reward Ratio Looks Great for Regeneron Pharmaceuticals Inc.

There’s risk, but there could be vast rewards for Regeneron Pharmaceuticals Inc.

Jan 8, 2014 by Peter Stephens

Can AbbVie Crush the Market in 2014?

AbbVie Inc. (ABBV) is a hot pharma stock.

Jan 7, 2014 by Peter Stephens

Why Obamacare and Hospira Inc. Are The Perfect Fit

... and why Hospira Inc. looks like a solid investment.

Jan 6, 2014 by Peter Stephens

Why Tapering Is Great News for Allergan Inc.

How growth stocks like Allergan could benefit from tapering.

Dec 18, 2013 by Peter Stephens

Amarin, Vivus, and Teva: The 3 Biggest Management Shake-Ups of 2013

Forget Steve Ballmer and Ron Johnson. These are the management shake-ups that health-care investors were watching this year.

Dec 18, 2013 by Peter Stephens

Why Merck Is a Hot Stock

Keep your eye on this pharma.

Dec 17, 2013 by Peter Stephens

Cash Is King for Pfizer

The cash keeps on coming at Pfizer, but is it being used wisely?

Dec 17, 2013 by Peter Stephens

3 Reasons Why Bristol-Myers Squibb Could Make an Awesome Comeback

Here’s why Bristol-Myers Squibb could become the King of Comebacks.

Dec 12, 2013 by Peter Stephens

3 Reasons Why Johnson & Johnson Could Help You Retire Early

Retirement may not be too far away for investors in Johnson & Johnson. Here’s why.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services